Thursday, May 23, 2013 Last update: 6:30 AM
Company Tech News as it Breaks
Astellas Pharma US, Inc.
News articles for Astellas Pharma US, Inc.:
Tuesday, May 7, 2013
- Data on MYRBETRIQ® (mirabegron) as Treatment for Overactive Bladder Presented at AUA 2013SAN DIEGO, May 7, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that results of three studies of MYRBETRIQ(®) (mirabegron) as a treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency were ... read more
Friday, April 19, 2013
- Astellas and Gift of Hope Organ & Tissue Donor Network Join Forces to Raise Awareness of Need for More Organ Donors in IllinoisNORTHBROOK, Ill., April 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Gift of Hope Organ & Tissue Donor Network, a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on ... read moreAstellas and Gift of Hope Organ & Tissue Donor Network Join Forces to Raise Awareness of Need for More Organ Donors in ChicagoNORTHBROOK, Ill., April 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Gift of Hope Organ & Tissue Donor Network, a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on ... read more
Tuesday, April 2, 2013
- Dr. Helen Fisher to Speak at Astellas Presents Executive Women's Day at Valero Texas OpenSAN ANTONIO, Texas and NORTHBROOK, Ill., April 2, 2013 /PRNewswire/ -- The PGA TOUR and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today will feature acclaimed researcher and author Dr. Helen Fisher at the Astellas Presents Executive Women's Day, a day-long forum ... read more
Tuesday, February 26, 2013
- PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Women's Day ProgramPALM BEACH GARDENS, Fla. and NORTHBROOK, Ill., Feb. 26, 2013 /PRNewswire/ --The PGA TOUR and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today will introduce the first Astellas Presents Executive Women's Day, a day-long forum focusing on professional, health-related and personal development ... read more
Tuesday, January 22, 2013
- Astellas' New Headquarters for the Americas Awarded LEED Gold CertificationNORTHBROOK, Ill., Jan. 22, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that its new headquarters for the Americas, located at the northwest corner of I-294 and Willow Road in Northbrook, has been awarded LEED Gold certification by the U.S. Green Building Council (USGBC). LEED, which stands for Leadership ... read more
Wednesday, January 16, 2013
- FDA Accepts Supplemental New Drug Application For Tarceva® (erlotinib) Tablets For Genetically Distinct Form Of Advanced Lung CancerNORTHBROOK, Ill., Jan. 16, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) for first-line use in people ... read more
Tuesday, December 4, 2012
- Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release CapsulesNORTHBROOK, Ill., Dec. 4, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for tacrolimus extended release capsules, ... read more